Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Gliomatosis cerebri
Journal Information
Vol. 25. Issue 3.
Pages 143-147 (April 2010)
Share
Share
Download PDF
More article options
Vol. 25. Issue 3.
Pages 143-147 (April 2010)
Full text access
Gliomatosis cerebri
Gliomatosis cerebri
Visits
1373
J. Bruna
Corresponding author
35078jbe@comb.cat

Author for correspondence.
, R. Velasco
Unidad Funcional de Neuro-Oncología, Servicio de Neurología, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat. Facultad de Medicina, Departamento de Biología celular, Fisiología e Inmunología, Universitat Autònoma de Barcelona, Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Barcelona, Spain
This item has received
Article information
Abstract
Introduction

Gliomatosis cerebri (GC) is a rare, diffusely growing glial tumour characterised by extensive brain infiltration. The diversity of histological subtype and grade on presentation among different subjects, in addition to the usually poor response to treatment make GC an uncertain entity where many questions still remain unanswered. One article in this issue of Neurología describes a series of 22 patients with GC, where clinical, therapeutic and outcome results are detailed.

Development

Clinical presentation of GC is non-specific and, although the neuroimage is characteristic, the spectrum of differential diagnosis is wide. Despite the fact that known prognostic factors in glioma also seem to be involved in GC, the heterogeneity of pathology and molecular findings on biopsy samples makes it difficult to characterise GC correctly. Therefore, variability of outcome and response to therapy is the rule. Evidence on therapeutic strategies is based on case-series. According to this, the optimal treatment is not well established. Part of current research is focused on identifying molecular predictor factors of response to chemotherapy.

Conclusions

The addition of chemotherapy in the classic treatment schedule based on radiotherapy seems to produce better responses in GC patients. However, the outcome of these patients remains poor with low survival rates. Phase III multi-centre trials to evaluate different therapeutic strategies in GC are essential. Further knowledge on the histological profile and molecular prognostic factors is also required. Patients should be stratified according to the prognostic factors identified.

Keywords:
Gliomatosis cerebri
Treatment
Prognosis
Survival
Molecular markers
Resumen
Introducción

La gliomatosis cerebri (GC) es un tumor glial difuso infrecuente, caracterizado por una gran capacidad infiltrativa. La variabilidad de características histológicas y de grado que presenta, junto con respuestas generalmente pobres a los tratamientos, convierte a la GC en un tumor poco conocido con diversas cuestiones por responder. En este volumen de Neurología se presenta un estudio sobre las características clínicas, evolución y respuestas al tratamiento en una serie de 22 pacientes con GC.

Desarrollo

La GC presenta una clínica poco distintiva, junto con una neuroimagen característica pero poco específica, lo que implica la realización de un diagnóstico diferencial amplio. Aunque en su evolución parecen estar implicados factores pronósticos similares a los de los otros gliomas, la heterogeneidad de sus hallazgos patológicos y moleculares dificulta su precisa caracterización. Así se explican sus variables comportamiento y respuesta al tratamiento. La evidencia sobre la eficacia de distintos abordajes terapéuticos se basa en series de casos clínicos; por lo tanto, el tratamiento no está bien establecido. Parte de la investigación actual se centra en identificar factores moleculares que puedan ser predictores de la respuesta a la quimioterapia.

Conclusiones

La incorporación de quimioterapia al tratamiento clásico basado en la radioterapia parece ofrecer mayores tasas de respuestas, aunque su impacto en la supervivencia sigue siendo escaso. Es necesaria la realización de estudios multicéntricos de fa-se III para evaluar las diferentes estrategias terapéuticas. Asimismo, hay que profundizar en el conocimiento sobre la histogénesis y los factores moleculares pronóstico para poder estratificar adecuadamente a los pacientes.

Palabras clave:
Gliomatosis cerebri
Tratamiento
Pronóstico
Supervivencia
Marcadores moleculares
Full text is only aviable in PDF
References
[1.]
M.T. Jennings, M. Frenchman, T. Shehab, M.D. Johonson, J. Creasy, K. LaPorte, et al.
Gliomatosis cerebri presenting as intractable epilepsy during early childhood.
J Child Neurol, 10 (1995), pp. 37-45
[2.]
M.A. Elshaikh, G.H.J. Stevens, D.M. Peerboom, B.H. Cohen, R.A. Prayson, S.Y. Lee, et al.
Gliomatosis cerebri. Treatment results with radiotherapy alone.
Cancer, 95 (2002), pp. 2027-2031
[3.]
WHO Classification of tumours of the central nervous system,
[4.]
S. Taillibert, C. Chodkiewicz, F. Laigle-Donadey, M. Napolitano, S. Cartalat-Carel, M. Sanson.
Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature.
J Neurooncol, 76 (2006), pp. 201-205
[5.]
M. Sanson, S. Cartalat-Carel, S. Taillibert, M. Napolitano, L. Djafari, J. Cougnard, et al.
Initial chemotherapy in gliomatosis cerebri.
Neurology, 63 (2004), pp. 270-275
[6.]
G.T. Armstrong, P.C. Philips, L.B. Rorke-Adams, A.R. Judkins, A.R. Localio, M.J. Fisher.
Gliomatosis cerebri: 20 years of experience at Children's Hospital of Philadelphia.
Cancer, 107 (2006), pp. 1597-1606
[7.]
G.E. Vates, S. Chang, K.R. Lamborn, M. Prados, M.S. Berger.
Gliomatosis cerebri: a review of 22 cases.
Neurosurgery, 53 (2003), pp. 261-271
[8.]
G. Kaloshi, S. Everhard, F. Laigle-Donadey, Y. Marie, S. Navarro, K. Mokhtari, et al.
Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri.
[9.]
M.L. Ware, Y. Hirose, B.W. Scheithauer, R. Yeh, M.C. Mayo, J.S. Smith, et al.
Genetic aberrations in gliomatosis cerebri.
Neurosurgery, 60 (2007), pp. 150-158
[10.]
S. Yang, S. Wetzel, S. Cha.
Dynamic contrast-enhanced T2-weighted MR Imaging of gliomatosis cerebri.
AJNR Am J Neuroradiol, 23 (2002), pp. 350-355
[11.]
D. Galanaud, O. Chinot, F. Nicoli, S. Confort-Gouny, Y. Le Fur, M. Barrie-Attarian, et al.
Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma.
J Neurosurg, 98 (2003), pp. 269-276
[12.]
G. Kaloshi, R. Guillevin, N. Martin-Duverneuil, F. Laigle-Donadey, D. Psimaras, Y. Marie, et al.
Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri.
Neurology, 73 (2009), pp. 445-449
[13.]
S. Park, Y.L. Suh, D.H. Ham, S.T. Kim.
Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types.
Clinical Neuropathology, 28 (2009), pp. 73-82
[14.]
C. Mawrin, E. Kirches, R. Schneider-Stock, C. Boltze, C.K. Vorwerk, A. Von Deimling, et al.
Alterations of cell cycle regulators in gliomatosis cerebri.
J Neurooncol, 72 (2005), pp. 115-122
[15.]
O.F. D’Urso, P.I. D’Urso, S. Marsigliante, C. Storelli, G. Luzi, D. Gianfreda, et al.
Correlative analysis of gene expression profile and prognosis in patients with gliomatosis cerebri.
Cancer, 115 (2009), pp. 3749-3757
[16.]
C. Mawrin.
Molecular genetic alterations in gliomatosis cerebri: what can we learn about the origin and course of the disease?.
Acta Neuropathol, 110 (2005), pp. 527-536
[17.]
S. Braeuninger, R. Schneider-Stock, E. Kirches, J.M. Powers, D.N. Korones, C. Mawrin.
Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri.
J Neurooncol, 82 (2007), pp. 23-27
[18.]
U. Herrlinger, J. Felsberg, W. Küker, A. Bornemann, L. Plasswilm, C.B. Knobbe, et al.
Gliomatosis cerebri: molecular pathology and clinical course.
Ann Neurol, 52 (2002), pp. 390-399
[19.]
C. Mawrin, H. Lins, E. Kirches, H.U. Schildhaus, C. Scherlach, D. Kanakis, et al.
Distribution of p53 alterations in a case of gliomatosis cerebri.
Hum Pathol, 34 (2003), pp. 102-106
[20.]
B.K. Hecht, C. Turc-Carel, M. Chatel, M. Lonjon, J.L. Roche, J. Gioanni, et al.
Chromosomes in gliomatosis cerebri.
Genes Chromosomes Cancer, 14 (1995), pp. 149-153
[21.]
H.S. Min, B. Kim, S.H. Park.
Array-based comparative genomic hybridization and immunohistochemical studies in gliomatosis cerebri.
J Neurooncol, 90 (2008), pp. 259-266
[22.]
D.S. Kong, M.H. Kim, W.Y. Park, Y.L. Suh, J.I. Lee, K. Park, et al.
The progression of gliomas is associated with cancer stem cell phenotype.
Oncology Reports, 19 (2008), pp. 639-643
[23.]
J.G. Cairncross, K. Ueki, M.C. Zlatescu, D.K. Lisle, D.M. Finkelstein, R.R. Hammond, et al.
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
J Natl Cancer Inst, 7 (1998), pp. 1473-1479
[24.]
N. Levin, J.M. Gomori, T. Siegal.
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology, 63 (2004), pp. 354-356
[25.]
M. Piccirilli, A. Landi, M. Salvati.
Gliomatosis cerebri treatment in 11 elderly patients.
J Exp Clin Cancer Res, 25 (2006), pp. 183-187
[26.]
M. Glas, K. Rasch, D. Wiewrodt, M. Weller, U. Herrlinger.
Procarbazine and CCNU as initial treatment in gliomatosis cerebri.
Oncology, 75 (2008), pp. 182-185
[27.]
R. Stupp, W.P. Mason, M.J. Van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, et al.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N Engl J Med, 352 (2005), pp. 987-996
[28.]
M. Seiz, P. Kohlhof, M.A. Brockmann, et al.
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
Anticancer Res, 29 (2009), pp. 3261-3267
Copyright © 2010. Sociedad Española de Neurología
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos